Related references
Note: Only part of the references are listed.First-Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis
W. Frank Peacock et al.
JOURNAL OF EMERGENCY MEDICINE (2022)
The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies
Darren M. Brenner et al.
SUPPORTIVE CARE IN CANCER (2021)
Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Cancer versus Noncancer Patients: An Analysis of Efficacy and Safety Variables from Two Studies
Bruce H. Chamberlain et al.
JOURNAL OF PAIN RESEARCH (2021)
Subcutaneous methylnaltrexone for opioid-induced constipation in advanced-illness patients with or without active cancer
Bruce H. Chamberlain et al.
PAIN MANAGEMENT (2020)
Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials
James Wild et al.
PAIN (2019)
Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer
N. Katakami et al.
ANNALS OF ONCOLOGY (2018)
Impact of opioid use on health care utilization and survival in patients with newly diagnosed stage IV malignancies
Dylan Zylla et al.
SUPPORTIVE CARE IN CANCER (2018)
Oxaliplatin-induced blood brain barrier loosening: a new point of view on chemotherapy-induced neurotoxicity
Jacopo Junio Valerio Branca et al.
Oncotarget (2018)
Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain
Richard Rauck et al.
PAIN PRACTICE (2017)
Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials
Martin Hale et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction
Hannah R. Wardill et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
The Mu Opioid Receptor: A New Target for Cancer Therapy?
Patrick A. Singleton et al.
CANCER (2015)
Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension
Janet Bull et al.
JOURNAL OF PALLIATIVE MEDICINE (2015)
Opioid-Induced Constipation Among Patients with Chronic Noncancer Pain in the United States, Canada, Germany, and the United Kingdom: Laxative Use, Response, and Symptom Burden Over Time
Karin S. Coyne et al.
PAIN MEDICINE (2015)
Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities
Alfred D. Nelson et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2015)
Subcutaneous Administration of Drugs in Palliative Care: Results of a Systematic Observational Study
Lena Bartz et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2014)
Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation
M. Camilleri et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2014)
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
William D. Chey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Mu Opioid Receptor Promotes Opioid and Growth Factor-Induced Proliferation, Migration and Epithelial Mesenchymal Transition (EMT) in Human Lung Cancer
Frances E. Lennon et al.
PLOS ONE (2014)
EORTC QLQ-C15-PAL quality of life score as a prognostic indicator of survival in patients with far advanced cancer
Yong Joo Lee et al.
SUPPORTIVE CARE IN CANCER (2014)
Opioid-Induced Constipation: Pathophysiology, Clinical Consequences, and Management
Lalit Kumar et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2014)
Characterization of Abdominal Pain During Methylnaltrexone Treatment of Opioid-Induced Constipation in Advanced Illness: A Post Hoc Analysis of Two Clinical Trials
Neal E. Slatkin et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2011)
The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1)
Timothy J. Bell et al.
PAIN MEDICINE (2009)
Methylnaltrexone for opioid-induced constipation in advanced illness
Jay Thomas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Opioid-induced bowel dysfunction:: prevalence, pathophysiology and burden
S. J. Panchal et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
Toward evidence-based prescribing at end of life: A comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients
Douglas J. Weschules et al.
PAIN MEDICINE (2006)
Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer
J Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology
T Meuser et al.
PAIN (2001)